China
Africa
Explore chapters and articles related to this topic
Separation Anxiety Disorder (SAD) and Adult Separation Anxiety Disorder (ASAD)
Published in Judy Z. Koenigsberg, Anxiety Disorders, 2020
Up until 2017, there has been no research that has offered an assessment of the effectiveness of pharmacotherapy or therapy treatment for patients with a main diagnosis of adult separation anxiety disorder (ASAD). In 2017, Schneier et al. presented preliminary findings that the SSRI, vilazodone, which has been shown to be beneficial for generalized anxiety disorder (Khan et al., 2016) may be effective for ASAD, but they caution that further study is required.
Antidepressant Drugs
Published in Sahab Uddin, Rashid Mamunur, Advances in Neuropharmacology, 2020
SPARIs, for example, vilazodone inhibit the reuptake of 5-HT and shows partial 5-HT1A receptor agonism (Schwartz and Stahl, 2011). Vilazodone appears to be safe, well tolerated, and have lower risk as compared with SSRIs or SNRIs (Robinson et al., 2011).
Pharmaceutical interventions
Published in Jane Hanley, Mark Williams, Fathers and Perinatal Mental Health, 2019
It should always be suggested that the medication be given time to work. This may take several weeks, during which time the sexual side effects might improve. It may be helpful to take the medication before engaging in any sexual activity, particularly if it is only taken once a day. If it becomes a problem it is worth discussing this with the general practitioner for advice on reducing the dosage or changing the antidepressant for one that has fewer side effects. Those medications with the lowest known rate of sexual side effects are Bupropion hydrochloride (Zyban) and Vilazodone.
Vilazodone poisoning: a systematic review
Published in Clinical Toxicology, 2020
Kevin Baumgartner, Michelle Doering, Evan Schwarz
The Food & Drug Administration approved vilazodone hydrochloride (Viibryd®) for the treatment of major depressive disorder (MDD) in 2011. Vilazodone is an indolealkylamine antidepressant which acts as both a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at the serotonin 5-HT1A receptor [1]. It is, thus, a serotonin partial agonist reuptake inhibitor (SPARI) [2]. Vilazodone has been shown to be effective in the treatment of major depressive disorder [1,3,4]. Vilazodone appears to have demonstrable antidepressant effects after 1 week of therapy [5], unlike the SSRIs, which have onset of action 3–4 weeks after initiation of therapy. The usual dose of vilazodone is 20 or 40 mg once daily [1]; tablets of 10, 20, and 40 mg are commercially available. Notably, vilazodone is not approved for use in the pediatric population.
Evaluation of dose and outcomes for pediatric vilazodone ingestions
Published in Clinical Toxicology, 2018
Christopher E. Gaw, Henry A. Spiller, Jason L. Russell, Thiphalak Chounthirath, Gary A. Smith
Although unintentional ingestions of SSRIs by children are typically well tolerated, our data suggest that exposure to vilazodone represents a unique and potentially serious threat to children <6 years of age. Young children exposed to even one pill of vilazodone can experience moderate to severe serotonin-related clinical effects, including coma and seizures. There appears to be a very narrow dosage range with vilazodone before toxic effects occur. Data in our study did not provide evidence of a threshold dose, below which a child can be routinely managed at home safely. Therefore, we recommend that vilazodone ingestions in this population be evaluated promptly in a clinical setting. Pediatric care providers should be educated about the potential serious outcomes associated with exposure to this medication. Additionally, until further research is conducted regarding its safety in children younger than 6 years old, off-label use of vilazodone in this age group should be discouraged.
Evaluation of vilazodone for the treatment of depressive and anxiety disorders
Published in Expert Opinion on Pharmacotherapy, 2019
Mirella Stuivenga, Erik J. Giltay, Olivia Cools, Laurence Roosens, Hugo Neels, Bernard Sabbe
Vilazodone has been directly compared with another antidepressant in two known studies. In the study conducted by Eyre et al. [27], vilazodone and paroxetine showed a significant decrease in HDRS-scores, however no significant differences were observed between the two groups. In the study of Bathla et al. [28] there was also no significant effect of vilazodone compared with escitalopram.